Private-equity investments in genomics-related tool and technology companies shrank 25 percent in 2003 compared with 2002, according to a venture capital-tracking newsletter.

Investment in drug-discovery tools, which include microarray and genotyping technologies, fell by 5 percent in the 12-month period ended Dec. 31, 2003 — the smallest margin of all genomics technologies — while bioinformatics companies took the biggest hit, experiencing an 80-percent drop-off in total venture-capital investment last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.